Glamhive Founder Stephanie Sprangers and Celebrity Stylist Jennifer Rade Announce Digital Fall Style and Beauty Summit
Glamhive announced its third online conference to be held on November 14. The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders, from Sarah Jessica Parker's stylist to Kim Kardashian's hairstylist. The innovative leaders will discuss all things fashion, wellness, beauty, and more. Stephanie Sprangers and Jennifer Rade will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201106005072/en/
The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders (Graphic: Mary Kay Inc.)
"I'm excited to co-host the Glamhive LIVE Fall Style and Beauty summit with Stephanie. We're bringing together the most amazing stylists, makeup artists, hairstylists, designers, & entrepreneurs in the world to share everything we've learned—from how we got started to all our tips and tricks on how to have great personal style," said Jennifer Rade, celebrity stylist and costume designer. Jennifer is one of the busiest stylists working today. Her clientele has ranged from A-List stars Angelina Jolie, Abbie Cornish, Cher, and Jenna Fischer, to musicians Lady A, Pink, Marilyn Manson, Dave Matthews, Amy Winehouse, Motley Crue, and Tina Turner. Her work has been featured in many publications, including W, Vanity Fair, Marie Claire, GQ, Esquire, and Harper's Bazaar.
"Glamhive's vision is to make personal styling available to everyone, everywhere, and our digital events are a wonderful extension of that. This year has enabled us to bring our events to everyone, everywhere so that people who are fashion and beauty enthusiasts or work in the industry can learn from the best in the business," said Stephanie Sprangers, Glamhive founder. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature 22 segments with 50-plus speakers. Below is an overview of some of the topics that will be covered by their all-star speaker line-up.
TOPICS:
- Zoom Style: Having Great (and Comfortable) Style
- The Making of a Fashion Stylist
- Foundations First
- How Your Home Environment Impacts Your Mood and Reflects Your Style
- How to Build the Wardrobe of Your Dreams
- 360 Style -- The Interplay of Hair, Makeup, and Wardrobe
- Entrepreneurship -- The Courage to Go For Your Dreams
- Future of the Red Carpet
- French Girl Chic and Our Obsession with Emily in Paris
- Shape Matters -- Love Yourself and Your Shape
- Style Your Health - Boosting Your Energy and Immunity
- Skincare Basics: Coaching Clients on Self-Care
- Iconic Style + How to Make a Statement with Your Style
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr, Keanu Reeves, Dwayne Johnson, Donald Glover, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, Liv Tyler, and more.
CELEBRITY STYLISTS:
Jennifer Rade, Ilaria Urbinati, Erin Walsh, Nicole Chavez, Jeanne Yang, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Sonia Young, Rachel Wirkus, Kesha McCloud
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Danesa Myricks, Andrew Fitzsimons, Daniel Martin, Colleen, Runne, Quinn Murphy, Sheridan Ward, Simedar Jackson, and Mia Santiago
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS
Cindy Eckhert (The Pink Ceiling Fund), Jonathan Sposato (Founder, PicMonkey), Carrie Colbert (Curated Capital), Summer Holl (President, Elyse Walker), Christian Juul Nielsen (Herve Leger | Aknvas), Lucy Aylen (Never Fully Dressed), Dr. Shrereene Idress, Dr. Avanti Kumar Singh
MODERATORS:
Brian Underwood (O the Oprah Magazine), Brooke Jaffe (former Fashion Director, Bloomingdales), Jack Eustace, Nicole Young (E! News), Kibwe Chase Marshall, Co-Founder, The Kelly Initiative), Jezlan Moyet.
Tickets to the conference are $99 for an all-day ticket and include a custom playlist by She-J Nikki Pennie. The presenting sponsor for the Glamhive Digital Fall Style and Beauty Summit is Mary Kay and its Mary Kay Global Design Studio. Other sponsors include NuBra USA, LEO, AKNVAS, NYDJ and more.
For more information, visit www.glamhive.com/upcoming.
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201106005072/en/
Contact information
Stephanie Sprangers, Founder + CEO, Glamhive
stephanie@glamhive.com
+1.206.851.0446
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom